
We need to keep talking about those unilateral 340B manufacturer notices
/ by Lisa Scholz, PharmD, MBA, FACHE, Head of Industry Relations
Several manufacturers are bypassing established HRSA guidance and placing restrictions on 340B drug access. Learn more about this pattern of interference.